CYCLACEL PHARMACEUTICALS INC (CYCC)
US23254L8019 - Common Stock
CYCC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. CYCC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYCC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CYCC has reported negative net income.
CYCC had a negative operating cash flow in the past year.
CYCC had negative earnings in each of the past 5 years.
In the past 5 years CYCC always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -258.41%, CYCC is doing worse than 92.47% of the companies in the same industry.
CYCC's Return On Equity of -3748.43% is on the low side compared to the rest of the industry. CYCC is outperformed by 84.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -258.41% | ||
| ROE | -3748.43% | ||
| ROIC | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CYCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYCC has been reduced compared to 1 year ago.
The number of shares outstanding for CYCC has been increased compared to 5 years ago.
CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
CYCC has a Current Ratio of 0.91. This is a bad value and indicates that CYCC is not financially healthy enough and could expect problems in meeting its short term obligations.
CYCC has a worse Current ratio (0.91) than 89.73% of its industry peers.
CYCC has a Quick Ratio of 0.91. This is a bad value and indicates that CYCC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CYCC (0.91) is worse than 88.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.91 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
CYCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -164.37%.
CYCC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.87% yearly.
EPS 1Y (TTM)-164.37%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q30.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, CYCC will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.04% on average per year.
CYCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 249.94% yearly.
EPS Next Y49.88%
EPS Next 2Y4.27%
EPS Next 3Y27.29%
EPS Next 5Y17.04%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y631.97%
Revenue Next 5Y249.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CYCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYCC's earnings are expected to grow with 27.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.27%
EPS Next 3Y27.29%
5. Dividend
5.1 Amount
No dividends for CYCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYCLACEL PHARMACEUTICALS INC
NASDAQ:CYCC (4/24/2024, 7:00:01 PM)
Premarket: 2.6 +0.3 (+13.05%)2.2999
+0.51 (+28.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.04M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -258.41% | ||
| ROE | -3748.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.91 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-164.37%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y